Trials / Completed
CompletedNCT00063154
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pertuzumab | Pertuzumab was supplied as a single-use liquid formulation. |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2003-06-25
- Last updated
- 2015-07-07
- Results posted
- 2015-06-08
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00063154. Inclusion in this directory is not an endorsement.